159 related articles for article (PubMed ID: 15631651)
1. [Experimental research on tyrosine-kinase inhibitor STI571 and P21WAF gene clone to treat chronic myeloid leukemia].
Wang W; Sun BZ; Liu XP; Feng Q; Shang ZC; Cao YX; Yao LB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):737-42. PubMed ID: 15631651
[TBL] [Abstract][Full Text] [Related]
2. Effects of STI571 and p27 gene clone on proliferation and apoptosis of K562 cells.
Wang W; Yao LB; Liu XP; Feng Q; Shang ZC; Cao YX; Sun BZ
World J Gastroenterol; 2005 Apr; 11(14):2130-5. PubMed ID: 15810079
[TBL] [Abstract][Full Text] [Related]
3. Study on the treatment of the p15 gene combined with Bcr-abl-specific siRNA and STI571 for chronic myeloid leukemia.
Wang W; Du Y; Li NN; Lv FF; Lin GQ
Genet Mol Res; 2014 May; 13(2):4089-101. PubMed ID: 24938701
[TBL] [Abstract][Full Text] [Related]
4. [Effects of specific siRNA targeting at bcr-abl fusion gene and its combination with p27 gene clone on chronic myeloid leukemia cell line K562].
Wang W; DU Y; Lin GQ; Li NN; Sun BZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Jun; 18(3):606-11. PubMed ID: 20561411
[TBL] [Abstract][Full Text] [Related]
5. [Effect of tyrosine-kinase Inhibitor on p15 gene transfected K562 cells].
Wang W; Sun BZ; Xie H; Yao LB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):42-6. PubMed ID: 17490518
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Koyama N; Koschmieder S; Tyagi S; Portero-Robles I; Chromic J; Myloch S; Nürnberger H; Rossmanith T; Hofmann WK; Hoelzer D; Ottmann OG
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2025-31. PubMed ID: 16609011
[TBL] [Abstract][Full Text] [Related]
7. Aminopeptidase inhibitors inhibit proliferation and induce apoptosis of K562 and STI571-resistant K562 cell lines through the MAPK and GSK-3beta pathways.
Sawafuji K; Miyakawa Y; Weisberg E; Griffin JD; Ikeda Y; Kizaki M
Leuk Lymphoma; 2003 Nov; 44(11):1987-96. PubMed ID: 14738154
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.
Majsterek I; Sliwinski T; Poplawski T; Pytel D; Kowalski M; Slupianek A; Skorski T; Blasiak J
Mutat Res; 2006 Jan; 603(1):74-82. PubMed ID: 16388976
[TBL] [Abstract][Full Text] [Related]
9. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
10. Divalproex sodium enhances the anti-leukemic effects of imatinib in chronic myeloid leukemia cells partly through SIRT1.
Wang W; Zhang J; Li Y; Yang X; He Y; Li T; Ren F; Zhang J; Lin R
Cancer Lett; 2015 Jan; 356(2 Pt B):791-9. PubMed ID: 25449787
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.
Pytel D; Wysocki T; Majsterek I
Comp Biochem Physiol C Toxicol Pharmacol; 2006 Sep; 144(1):85-92. PubMed ID: 16904383
[TBL] [Abstract][Full Text] [Related]
12. [STI571 induces apoptosis of K562 cells through down-regulation of anti-apoptotic protein Mcl-1 and Bcl-xl expression].
Zhang BZ; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1182-5. PubMed ID: 18088462
[TBL] [Abstract][Full Text] [Related]
13. Imatinib (STI571)-mediated changes in glucose metabolism in human leukemia BCR-ABL-positive cells.
Gottschalk S; Anderson N; Hainz C; Eckhardt SG; Serkova NJ
Clin Cancer Res; 2004 Oct; 10(19):6661-8. PubMed ID: 15475456
[TBL] [Abstract][Full Text] [Related]
14. c-Jun blocks cell differentiation but not growth inhibition or apoptosis of chronic myelogenous leukemia cells induced by STI571 and by histone deacetylase inhibitors.
Huang HM; Liu JC
J Cell Physiol; 2009 Mar; 218(3):568-74. PubMed ID: 19006173
[TBL] [Abstract][Full Text] [Related]
15. RPS27a promotes proliferation, regulates cell cycle progression and inhibits apoptosis of leukemia cells.
Wang H; Yu J; Zhang L; Xiong Y; Chen S; Xing H; Tian Z; Tang K; Wei H; Rao Q; Wang M; Wang J
Biochem Biophys Res Commun; 2014 Apr; 446(4):1204-10. PubMed ID: 24680683
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of dasatinib- and imatinib-resistant chronic myelogenous leukemia cells.
Okabe S; Tauchi T; Ohyashiki K
Clin Cancer Res; 2008 Oct; 14(19):6181-6. PubMed ID: 18829496
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of doxorubicin and STI571 on growth, differentiation and apoptosis of CML cell line K562.
Jakubowska J; Stasiak M; Szulawska A; Bednarek A; Czyz M
Acta Biochim Pol; 2007; 54(4):839-46. PubMed ID: 17957275
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
Yu C; Rahmani M; Almenara J; Subler M; Krystal G; Conrad D; Varticovski L; Dent P; Grant S
Cancer Res; 2003 May; 63(9):2118-26. PubMed ID: 12727828
[TBL] [Abstract][Full Text] [Related]
19. Role of p21(WAF1/CIP1) as an attenuator of both proliferative and drug-induced apoptotic signals in BCR-ABL-transformed hematopoietic cells.
Forster K; Obermeier A; Mitina O; Simon N; Warmuth M; Krause G; Hallek M
Ann Hematol; 2008 Mar; 87(3):183-93. PubMed ID: 17960378
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase inhibitor STI571 (Imatinib) cooperates with wild-type p53 on K562 cell line to enhance its proapoptotic effects.
Brusa G; Mancini M; Campanini F; Calabrò A; Zuffa E; Barbieri E; Santucci MA
Acta Haematol; 2005; 114(3):150-4. PubMed ID: 16227678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
